20.500.12556/RUL-134824 AKR1C3 is associated with better survival of patients with endometrial carcinomas The aldo-keto reductase (AKR) superfamily is gaining attention in cancer research. AKRs are involved in important biochemical processes and have crucial roles in carcinogenesis and chemoresistance. The enzyme AKR1C3 has many functions, which include production of prostaglandins, androgens and estrogens, and metabolism of different chemotherapeutics; AKR1C3 is thus implicated in the pathophysiology of different cancers. Endometrial and ovarian cancers represent the majority of gynecological malignancies in developed countries. Personalized treatments for these cancers depend on identification of prognostic and predictive biomarkers that allow stratification of patients. In this study, we evaluated the immunohistochemical (IHC) staining of AKR1C3 in 123 paraffin-embedded samples of endometrial cancer and 99 samples of ovarian cancer, and examined possible correlations between expression of AKR1C3 and other clinicopathological data. The IHC expression of AKR1C3 was higher in endometrial cancer compared to ovarian cancer. In endometrioid endometrial carcinoma, high AKR1C3 IHC expression correlated with better overall survival (hazard ratio, 0.19; 95% confidence interval, 0.06−0.65, p = 0.008) and with disease-free survival (hazard ratio, 0.328; 95% confidence interval, 0.12–0.88, p = 0.027). In patients with ovarian cancer, there was no correlation between AKR1C3 IHC expression and overall and disease-free survival or response to chemotherapy. These results demonstrate that AKR1C3 is a potential prognostic biomarker for endometrioid endometrial cancer. endometrial carcinoma high grade serous ovarian carcinoma prognosis immunohistochemistry biomarker aldo-keto reductase 1C3 (AKR1C3) karcinom endometrija serozni karcinom jajčnikov visoke stopnje napoved true false true Angleški jezik Slovenski jezik Članek v reviji 2022-02-03 12:13:55 2022-02-03 12:13:58 2022-09-14 04:10:09 0000-00-00 00:00:00 2020 0 0 15 str. iss. 12, art. 4105 Vol. 9 Dec. 2020 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-006 2077-0383 10.3390/jcm9124105 43786755 RAZ_Hojnik_Marko_2020.pdf RAZ_Hojnik_Marko_2020.pdf 1 F83BF177E60225371EDBFD6BC45EA3F6 f1bace198179910d5a7e5de2cc655e299b4ab87367b2df3b1bb5e632c02bd88c 83382c1b-84e2-11ec-abdb-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=153495 https://www.mdpi.com/2077-0383/9/12/4105 1 2a0a213c-84e2-11ec-abdb-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=153494 Medicinska fakulteta 0 0 0